Cambridge Investment Research Advisors Inc. Grows Position in Intuitive Surgical, Inc. $ISRG

Cambridge Investment Research Advisors Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 42,136 shares of the medical equipment provider’s stock after buying an additional 2,636 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Intuitive Surgical were worth $23,864,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Intuitive Surgical by 0.8% during the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock valued at $15,026,776,000 after purchasing an additional 263,828 shares in the last quarter. Capital World Investors lifted its position in Intuitive Surgical by 1.5% during the third quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock valued at $3,456,223,000 after purchasing an additional 116,034 shares in the last quarter. Fisher Asset Management LLC lifted its position in Intuitive Surgical by 1.1% during the third quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock valued at $1,739,475,000 after purchasing an additional 40,702 shares in the last quarter. Amundi lifted its position in Intuitive Surgical by 29.7% during the third quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after purchasing an additional 739,444 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in Intuitive Surgical by 11.1% during the fourth quarter. Jennison Associates LLC now owns 3,209,137 shares of the medical equipment provider’s stock valued at $1,817,527,000 after purchasing an additional 321,759 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Myriam Curet sold 105 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total value of $51,864.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Amy L. Ladd sold 119 shares of Intuitive Surgical stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total value of $55,156.50. Following the completion of the sale, the director directly owned 120 shares in the company, valued at $55,620. This trade represents a 49.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 5,647 shares of company stock valued at $2,760,359. 0.60% of the stock is currently owned by corporate insiders.

Intuitive Surgical Stock Up 4.5%

NASDAQ:ISRG opened at $439.92 on Tuesday. The business’s 50-day simple moving average is $462.50 and its two-hundred day simple moving average is $513.03. The stock has a market cap of $155.80 billion, a PE ratio of 53.32, a P/E/G ratio of 3.36 and a beta of 1.51. Intuitive Surgical, Inc. has a 52 week low of $417.74 and a 52 week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period last year, the firm earned $1.81 earnings per share. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of several analyst reports. Zacks Research downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. UBS Group lowered their target price on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. The Goldman Sachs Group lifted their target price on Intuitive Surgical from $609.00 to $621.00 and gave the company a “buy” rating in a research report on Wednesday, April 22nd. Leerink Partners lowered their target price on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Finally, Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price target on the stock in a report on Wednesday, March 11th. Nineteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $579.33.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.